

Matthew T. Browne

Partner

matthew.browne@foley.com

San Diego

858.847.6734



Matt Browne represents emerging and late-stage private companies and public companies in a wide range of corporate and securities matters. His experience spans corporate formation and governance, private financings, mergers and acquisitions, SPAC transactions, public company reporting and disclosure, public offerings, strategic collaborations, commercial agreements, and employment and compensation arrangements.

Matt counsels management teams and boards at every stage of the business lifecycle, helping them achieve their goals in a constructive, practical, and creative manner. He works with companies across a broad range of industries, including software, cybersecurity, health care, semiconductors, financial services, financial technology, consumer products, medical devices, diagnostics, and biotechnology. Matt also regularly advises on drug royalty sales and monetizations.

Representative Experience

- Represented Shoreline Biosciences in its sale to Concentra Biosciences.*
- Represented MacroGenics in the monetization of ZYNYZ royalties to Sagard Healthcare.*
- Represented Rady Children's Institute for Genomic Medicine in the formation and financing of Inflection Medicine.*
- Represented AttackIQ in the acquisition of the assets of DeepSurface.*
- Represented Mission Secure in its sale to ServiceNow.*
- Represented Cortica in its US\$80m financing.*
- Represented TriSalus in a warrant/exchange tender offer relating to SPAC warrants.*
- Represented TriSalus in its US\$50m senior secured credit facility with OrbiMed.*
- Represented Cirrus Bio in its sale to Maverix Medical.*
- Represented Talphera in the partial monetization of Dsuvia royalties and milestones to XOMA Royalty.*
- Represented MannKind in the partial monetization of Tyvaso DPI royalties to Sagard Healthcare.*

- Represented Ovid Therapeutics in the partial monetization of soticlestat royalties to Ligand Pharmaceuticals.*
- Represented TriSalus in its de?SPAC transaction with MedTech Acquisition Corporation.*
- Represented Cortica in its acquisition of Springtide Child Development and its US\$75m Series D financing.*
- Represented TRACON Pharmaceuticals in its US\$30m litigation financing.*
- Represented Athenex in the sale of Klisyri revenue interests to Sagard Healthcare and Oaktree Capital.*
- Represented Sixth Street in a US\$250m royalty financing on sales of Ayvakit/Ayvakyt and Blu?263 and a US\$400m senior secured credit facility.*
- Represented AgileThought in its de?SPAC transaction with LIV Capital Acquisition Corp.*
- Represented the management team of Confluence Technologies in the company's acquisition by Clearlake Capital.*
- Represented Billtrust in its de?SPAC transaction with South Mountain Merger Corp.*
- Represented XMatters in its sale to Everbridge.*
- Represented AttackIQ in its US\$44m Series C financing.*
- Represented Cortica in its US\$60m Series C financing.*
- Represented Paradigm Diagnostics in its sale to Exact Sciences.*
- Represented Viomics in its sale to Exact Sciences.*
- Represented Verb Surgical in its sale to Johnson & Johnson.*
- Represented TPG Sixth Street Partners in the sale of Kadcyra royalties.*
- Represented MedImpact in a cash tender offer for all outstanding equity held by non?*

*Matters handled prior to joining Foley.

Awards and Recognition

- *Best Lawyers in America*®, Corporate Law

Affiliations

- Member, Executive Committee, Connect San Diego
- Former Trustee, Sanford Burnham Prebys Medical Discovery Institute
- Member, American Bar Association
- Member, California Bar Association
- Member, New York State Bar Association

Sectors

- [Innovative Technology](#)

Practice Areas

- [Corporate](#)

- [Transactions](#)
- [Venture & Growth Capital](#)

Education

- Harvard Law School (J.D., cum laude, 1995)
- Yale University (B.A., summa cum laude, 1990)
 - Phi Beta Kappa

Admissions

- California
- New York